Drug Evaluation

James Buchanan Brady Department of Urology, Weill Cornell Medical College of Cornell University, 525 East 68th Street, F9 West, Box 261, NY 10065, USA

Search for more papers by this author

Steven A Kaplan

James Buchanan Brady Department of Urology, Weill Cornell Medical College of Cornell University, 525 East 68th Street, F9 West, Box 261, NY 10065, USA

Search for more papers by this author

Jack Barkin

* Author for correspondence

Department of Surgery, University of Toronto, Humber River Regional Hospital, 960 Lawrence Avenue West, Suite 404, Toronto, Ontario, M6A 3B5, Canada.

Search for more papers by this author

Email the corresponding author at j.barkin@rogers.com

Published Online:14 Dec 2012https://doi.org/10.2217/ahe.12.61

View article

Abstract

Lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH) commonly affect older men, notably 50% of men in their sixties and 80% of men in their nineties. Many men will seek medical care for their symptoms and decreased quality of life. If left untreated, many men will experience progression of their BPH resulting in acute urinary retention or need for surgical intervention. Currently, two classes of drugs, α-adrenergic blockers (‘openers’) and 5-α reductase inhibitors (‘shrinkers’), are prescribed to treat lower urinary tract symptoms secondary to BPH. Due to their different mechanisms of action, trials of combination therapy have been conducted to assess their effect compared with monotherapy. The Medical Therapy of Prostatic Symptoms and The Combination of Avodart and Tamsulosin studies demonstrated significantly more effective reduction in symptoms and lower rates of clinical progression in the combination therapy treatment groups. Current data supports combination therapy in men with moderately enlarged prostates and moderate-to-severe symptoms.

Keywords:

References

1 Roehrborn CG. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Campbell’s Urology (8th Edition). Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ (Eds). WB Saunders, PA, USA, 1229 (2002).
Google Scholar
2 Girman CJ. Natural history and epidemiology of benign prostatic hyperplasia: relationship among urologic measures. Urology51(4 Suppl. 1),8–12 (1998).
Medline CASGoogle Scholar
3 Oishi KBP, Barry M. Epidemiology and natural history of benign prostatic hyperplasia. 4th International Consultation on Benign Prostatic Hyperplasia. Plymbridge distributors Ltd, Plymouth, UK, 23–59 (1998).
Google Scholar
4 McVary KT, Roehrborn CG, Avins AL et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J. Urol.185(5),1793–1803 (2011).
MedlineGoogle Scholar
5 Roehrborn CG. The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia. Int. J. Impot. Res.20(Suppl. 3),S19–S26 (2008).
MedlineGoogle Scholar
6 Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur. Urol.51(6), 1645–1652 discussion; 1652–1653 (2007).
Google Scholar
7 Lieber MM, Jacobsen SJ, Roberts RO, Rhodes T, Girman CJ. Prostate volume and prostate-specific antigen in the absence of prostate cancer: a review of the relationship and prediction of long-term outcomes. Prostate49(3),208–212 (2001).
Medline CASGoogle Scholar
8 Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology53(3),581–589 (1999).
Medline CASGoogle Scholar
9 Committee APG. AUA guideline on management of benign prostatic hyperplasia. Chapter 1: diagnosis and treatment recommendations. J. Urol.170(2 Pt 1),530–547 (2003).
MedlineGoogle Scholar
10 Foster CS. Pathology of benign prostatic hyperplasia. Prostate (Suppl. 9),S4–S14 (2000).
Google Scholar
11 Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet361(9366),1359–1367 (2003).
Medline CASGoogle Scholar
12 McVary KT. BPH: epidemiology and comorbidities. Am. J. Manag. Care12(Suppl. 5),S122–S128 (2006).
MedlineGoogle Scholar
13 Barkin J. Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability. Patient Prefer Adherence5,483–490 (2011).
MedlineGoogle Scholar
14 Berges R. Impact of therapy used in clinical practice on lower urinary tract symptoms/benign prostatic hypertrophy (LUTS/BPH) on disease progression. Eur. Urol.2(7),19–24 (2003).
CASGoogle Scholar
15 Raz S, Zeigler M, Caine M. Pharmacological receptors in the prostate. Br. J. Urol.45(6),663–667 (1973).
Medline CASGoogle Scholar
16 Shapiro E. Embryologic development of the prostate. Urol. Clin. North Am.17,487–493 (1990).
Medline CASGoogle Scholar
17 Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G; ARIA3001 ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology60(3),434–441 (2002).
MedlineGoogle Scholar
18 Andersen J, Ekman P, Wolf H et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo controlled study. Urology46,631–637 (1995).
Medline CASGoogle Scholar
19 Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev. Urol.6(Suppl. 9),S31–S39 (2004).
MedlineGoogle Scholar
20 Anderson KE. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev.45(3),253–308 (1993).
Medline CASGoogle Scholar
21 Forray C, Bard JA, Wetzel JM et al. The α1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α1c subtype. Mol. Pharmacol.45(4),703–708 (1994).
Medline CASGoogle Scholar
22 Elhilali M, Ramsey EW, Barkin J et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia. Urology47,335–342 (1996).
Medline CASGoogle Scholar
23 Roehrborn C. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology58,953–959 (2001).
Medline CASGoogle Scholar
24 Roehrborn C, Siegel R. Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology48,406–415 (1996).
Medline CASGoogle Scholar
25 Debruyne F. α blockers: are all created equal? Urology56(5 Suppl. 1),S20–S22 (2000).
Medline CASGoogle Scholar
26 Barkin J. Benign prostatic hyperplasia and Lower urinary tract symptoms. Evidence for best case management. Can. J. Urol.18(Suppl.),14–19 (2011).
MedlineGoogle Scholar
27 Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. α1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi126,209–216 (2006).
Medline CASGoogle Scholar
28 Lepor H, Hill LA. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy30(12),1303–1312 (2010).
Medline CASGoogle Scholar
29 Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective α 1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 Phase 3 studies. J. Urol.181(6),2634–2640 (2009).
Medline CASGoogle Scholar
30 Roehrborn CG, Kaplan SA, Lepor H, Volinn W. Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH. Prostate Cancer Prostatic Dis.14(2),143–148 (2011).
Medline CASGoogle Scholar
31 McConnell J. Medical management of benign prostatic hyperplasia with androgen suppression. Prostate3(Suppl.),49–59 (1990).
Medline CASGoogle Scholar
32 Kaplan S, McConnell J. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J. Urol.175(1),217–220 (2006).
Medline CASGoogle Scholar
33 Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α-adrenoceptor antagonists. BJU Int.95(Suppl. 4),S29–S36 (2005).
Medline CASGoogle Scholar
34 Fenter TC, Davis EA, Shah MB, Lin PJ. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. Am. J. Manag. Care14(5 Suppl. 2),S154–S159 (2008).
MedlineGoogle Scholar
35 Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology72(4),808–812 (2008).
MedlineGoogle Scholar
36 Roehrborn CG, Marks LS, Fenter T. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology63(4),709–715 (2004).
MedlineGoogle Scholar
37 Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J. Clin. Endocrinol Metab.89(5),2179–2184 (2004).
Medline CASGoogle Scholar
38 Michel MC, de la Rosette JJ. Efficacy and safety of tamsulosin in the treatment of urological diseases. Expert Opin. Pharmacother.5(1),151–160 (2004).
Medline CASGoogle Scholar
39 Soeishi Y, Matsushima H, Watanabe T, Higuchi S, Cornelissen K, Ward J. Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica26(6),637–645 (1996).
Medline CASGoogle Scholar
40 Wilde MI, McTavish D. Tamsulosin. A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia. Drugs52(6),883–898 (1996).
Medline CASGoogle Scholar
41 Evans HC, Goa KL. Dutasteride. Drugs Aging20(12),905–916; discussion 917–918 (2003).
Medline CASGoogle Scholar
42 Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson M. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. Br. J. Clin. Pharmacol.47(1),53–58 (1999).
Medline CASGoogle Scholar
43 Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of Phase III trial. Tamsulosin Investigator Group. Urology51(6),901–906 (1998).
Medline CASGoogle Scholar
44 Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology51(6),892–900 (1998).
Medline CASGoogle Scholar
45 Narayan P, Tewari A. A second Phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93–01 Study Group. J. Urol.160(5),1701–1706 (1998).
Medline CASGoogle Scholar
46 O’Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int.92(3),262–266 (2003).
MedlineGoogle Scholar
47 Brawer MK, Lin DW, Williford WO, Jones K, Lepor H. Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate39(4),234–239 (1999).
Medline CASGoogle Scholar
48 McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med.349(25),2387–2398 (2003).
Medline CASGoogle Scholar
49 Siami P, Roehrborn CG, Barkin J et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp. Clin. Trials28(6),770–779 (2007).
Medline CASGoogle Scholar
50 Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol.57(1),123–131 (2010).
Medline CASGoogle Scholar
51 Barkin J, Roehrborn CG, Siami P et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial. BJU Int.103(7),919–926 (2009).
Medline CASGoogle Scholar
52 Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur. Urol.57(1),123–131. (2009).
MedlineGoogle Scholar
53 Elshaikh MA, Ulchaker JC, Reddy CA et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int. J. Radiat. Oncol. Biol. Phys.62(1),164–169 (2005).
Medline CASGoogle Scholar
54 Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J. Cataract Refract. Surg.31(4),664–673 (2005).
MedlineGoogle Scholar
55 Roehrborn CG, Barkin J, Siami P et al. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int.107(6),946–954 (2011).
Medline CASGoogle Scholar
56 Andriole GL, Bostwick DG, Brawley OW et al. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med.362(13),1192–1202 (2010).
Medline CASGoogle Scholar
57 Ventura S, Oliver Vl, White CW, Xie JH, Haynes JM, Exintaris B. Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). Br. J. Pharmacol.163(5),891–907 (2011).
Medline CASGoogle Scholar
58 Gacci M, Corona G, Salvi M et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur. Urol.61(5),994–1003 (2012).
Medline CASGoogle Scholar
59 Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H. Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group. J. Urol.144(4),908–911; discussion 911–912 (1990).
Medline CASGoogle Scholar
60 Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). The European Tamsulosin Study Group. Br. J. Urol.76(3),325–336 (1995).
Medline CASGoogle Scholar
101 Boehringer-Ingelheim, Flomax Prescribing Information. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Flomax+Caps/Flomax.pdf
Google Scholar
102 GlaxoSmithKline. Avodart Highlights of Prescribing information. http://us.gsk.com/products/assets/us_avodart.pdf
Google Scholar

Vol. 8, No. 6

Metrics

Downloaded 83 times

History

Published online 14 December 2012

Published in print December 2012

Information

Keywords

Financial & competing interests disclosure

GSK conducted a factual review of this manuscript. All authors have acted as speakers, teachers and principal investigators for Merck, GSK, Abbott, Lilly, Bayer and Astellas. None have a financial interest in any Pharma company. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Combination treatment with tamsulosin and dutasteride for benign prostatic hyperplasia

Abstract

References